节拍化疗联合治疗乳腺癌的研究现状。
Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer.
机构信息
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
出版信息
Oncol Res Treat. 2022;45(11):681-692. doi: 10.1159/000526481. Epub 2022 Aug 19.
Abstract
BACKGROUND
Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncology. Numerous clinical trials of MCT in combination with other treatments, including targeted therapies, biologics, and endocrine therapy, are in progress to obtain better results.
SUMMARY
We comprehensively described the clinical benefits of MCT in combination with other treatments in different molecular subtypes of breast cancer and assessed the feasibility of its adoption in varying phases of treatment. Due to the promising preclinical and clinical investigations, it is expected that MCT in combination with other treatments will enhance the advantages of this strategy and apply it to clinical practice.
KEY MESSAGE
MCT, in combination with other therapeutic interventions, will fully exploit the benefits of this strategy, ushering in a new paradigm in oncology treatment and driving the transformation of cancer into a more manageable chronic disease using newly developed treatment approaches.
摘要
背景
节拍化疗（MCT），也称为最小毒性的持续低剂量给药，是一种新的常规化疗方式，已被证实为一种可行的治疗选择，并在肿瘤学领域得到了广泛的认可和关注。目前正在进行许多 MCT 与其他治疗方法（包括靶向治疗、生物制剂和内分泌治疗）联合应用的临床试验，以期获得更好的效果。
摘要
我们全面描述了 MCT 联合其他治疗方法在不同分子亚型乳腺癌中的临床获益，并评估了其在不同治疗阶段应用的可行性。由于有前景的临床前和临床研究，预计 MCT 联合其他治疗方法将增强这种策略的优势，并将其应用于临床实践。
关键信息
MCT 联合其他治疗干预措施，将充分发挥这种策略的优势，为肿瘤治疗带来新的范例，并通过新开发的治疗方法将癌症转变为更易于管理的慢性病。
相似文献
1
Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer.节拍化疗联合治疗乳腺癌的研究现状。
Oncol Res Treat. 2022;45(11):681-692. doi: 10.1159/000526481. Epub 2022 Aug 19.
2
Metronomic Chemotherapy for Metastatic Breast Cancer.节拍化疗治疗转移性乳腺癌。
Oncol Res Treat. 2022;45(1-2):12-17. doi: 10.1159/000520236. Epub 2021 Nov 18.
3
Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?节拍化疗联合内分泌治疗：我们是否在挑战某些教条？
Expert Rev Anticancer Ther. 2020 Jul;20(7):563-573. doi: 10.1080/14737140.2020.1782200. Epub 2020 Jun 30.
4
Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.节拍化疗治疗晚期乳腺癌和非小细胞肺癌：长春瑞滨作为近期进展范例
Expert Rev Anticancer Ther. 2021 Jan;21(1):71-79. doi: 10.1080/14737140.2021.1835478. Epub 2020 Oct 22.
5
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.节拍化疗与药物重新利用：肿瘤学中的范式转变。
Heliyon. 2024 Jan 14;10(3):e24670. doi: 10.1016/j.heliyon.2024.e24670. eCollection 2024 Feb 15.
6
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.采用小剂量节拍式化疗对乳腺癌进行抗血管生成治疗。
Breast. 2005 Dec;14(6):466-79. doi: 10.1016/j.breast.2005.08.026. Epub 2005 Sep 30.
7
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.节拍化疗在胃肠道癌中的应用原理。
Expert Opin Pharmacother. 2018 Sep;19(13):1451-1463. doi: 10.1080/14656566.2018.1512585. Epub 2018 Aug 30.
8
9
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.口服节拍性长春瑞滨治疗晚期乳腺癌和非小细胞肺癌：现状与未来发展
Future Oncol. 2016 Feb;12(3):373-87. doi: 10.2217/fon.15.306. Epub 2015 Nov 19.
10
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.环磷酰胺-甲氨蝶呤“小剂量持续”化疗用于转移性乳腺癌的姑息治疗：一项比较性药物经济学评价
Ann Oncol. 2005 Aug;16(8):1243-52. doi: 10.1093/annonc/mdi240. Epub 2005 May 19.
引用本文的文献
1
Mechanistic insights into taxane-induced psychiatric adverse events: a global pharmacovigilance and experimental investigation.紫杉烷类药物所致精神方面不良事件的机制性见解：一项全球药物警戒及实验研究
Mol Psychiatry. 2025 Sep 16. doi: 10.1038/s41380-025-03252-1.
2
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.曲美木单抗联合度伐利尤单抗与节拍口服长春瑞滨联合使用：II期MOVIE研究乳腺癌队列的结果。
Breast. 2025 Aug 5;83:104549. doi: 10.1016/j.breast.2025.104549.
3
Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal.pT1-T2 N0 M0 期 HER2 阳性且 ER/PR 阳性乳腺癌术后辅助节拍化疗联合靶向治疗、抗激素治疗及放疗，联合或不联合免疫治疗：一项新的治疗方案建议
Cancers (Basel). 2025 Apr 15;17(8):1323. doi: 10.3390/cancers17081323.
4
Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.卡培他滨节拍化疗治疗肝细胞癌的疗效和安全性：系统评价和荟萃分析。
J Gastrointest Cancer. 2024 Dec;55(4):1485-1497. doi: 10.1007/s12029-024-01103-w. Epub 2024 Aug 20.
5
The inherent fragility of collective proliferative control.集体增殖控制的内在脆弱性。
bioRxiv. 2024 Aug 19:2024.01.23.576783. doi: 10.1101/2024.01.23.576783.
6
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.节拍化疗与药物重新利用：肿瘤学中的范式转变。
Heliyon. 2024 Jan 14;10(3):e24670. doi: 10.1016/j.heliyon.2024.e24670. eCollection 2024 Feb 15.
7
Induced Vascular Normalization-Can One Force Tumors to Surrender to a Better Microenvironment?诱导血管正常化——能否迫使肿瘤向更好的微环境屈服？
Pharmaceutics. 2023 Jul 26;15(8):2022. doi: 10.3390/pharmaceutics15082022.
8
A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.一项 II 期研究，评估了由口服长春瑞滨和卡培他滨组成的双联节拍化疗方案，用于治疗 HER2 阴性转移性乳腺癌的中国女性患者。
Thorac Cancer. 2023 Aug;14(23):2259-2268. doi: 10.1111/1759-7714.15011. Epub 2023 Jul 4.
9
Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives.基于纳米制剂的节拍化疗：机制、挑战、最新进展及未来展望
Pharmaceutics. 2023 Apr 8;15(4):1192. doi: 10.3390/pharmaceutics15041192.
10
Targeting Breast Cancer: An Overlook on Current Strategies.靶向乳腺癌：当前策略概述
Int J Mol Sci. 2023 Feb 11;24(4):3643. doi: 10.3390/ijms24043643.
本文引用的文献
1
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.EORTC 75111-10114 ETF/BCG 随机 II 期研究的长期结果数据：曲妥珠单抗和帕妥珠单抗联合或不联合节拍化疗用于 HER2 阳性转移性乳腺癌老年患者，进展后使用 T-DM1。
Breast. 2022 Aug;64:100-111. doi: 10.1016/j.breast.2022.05.004. Epub 2022 May 20.
2
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.口服节拍式长春瑞滨联合曲妥珠单抗（mNH）治疗人表皮生长因子受体 2 阳性转移性乳腺癌的安全性和有效性研究：一项 II 期试验。
Breast Cancer Res Treat. 2021 Jul;188(2):441-447. doi: 10.1007/s10549-021-06216-5. Epub 2021 Apr 25.
3
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌（PHOEBE）：一项多中心、开放标签、随机、对照、Ⅲ期临床试验。
Lancet Oncol. 2021 Mar;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6. Epub 2021 Feb 11.
4
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).曲马多口服化疗联合环磷酰胺和卡培他滨（HEX）作为曲妥珠单抗一线治疗 HER-2 阳性晚期乳腺癌：意大利南部肿瘤学组（GOIM）的 II 期试验。
Breast. 2020 Oct;53:18-22. doi: 10.1016/j.breast.2020.06.002. Epub 2020 Jun 5.
5
Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment.节拍性紫杉醇通过改变肿瘤免疫微环境提高PD-1单克隆抗体在乳腺癌中的疗效。
Am J Transl Res. 2020 Feb 15;12(2):519-530. eCollection 2020.
6
Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.节拍式卡培他滨作为胶质母细胞瘤患者的免疫调节剂可减少髓源抑制细胞。
JCI Insight. 2019 Nov 14;4(22):130748. doi: 10.1172/jci.insight.130748.
7
Can we cure stage IV triple-negative breast carcinoma?: Another case report of long-term survival (7 years).我们能治愈IV期三阴性乳腺癌吗？：另一例长期生存（7年）的病例报告。
Medicine (Baltimore). 2019 Sep;98(38):e17251. doi: 10.1097/MD.0000000000017251.
8
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.口服节拍式长春瑞滨联合内分泌治疗激素受体阳性 HER2 阴性乳腺癌：SOLTI-1501 VENTANA 机会之窗试验。
Breast Cancer Res. 2019 Sep 18;21(1):108. doi: 10.1186/s13058-019-1195-z.
9
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.转移性三阴性乳腺癌的免疫诱导策略，以提高对 PD-1 阻断的敏感性：TONIC 试验。
Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13.
10
Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.转移性三阴性乳腺癌长期生存病例报告：转移性疾病的治疗可能性
Medicine (Baltimore). 2019 Apr;98(16):e15302. doi: 10.1097/MD.0000000000015302.
Zotero 插件